Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. News and Stories
  4. New evidence supports ablation for initial atrial fibrillation treatment

New evidence supports ablation for initial atrial fibrillation treatment

News Releases Nov 24, 2020 4 minutes

News release | Patients who received cryoballoon ablation had fewer or no recurrences of atrial fibrillation.

Vancouver, BC - Cryoballoon ablation produced better outcomes than antiarrhythmic drug (AAD) therapy among individuals receiving their initial treatment for atrial fibrillation (AF), according to the results of a new study led by Vancouver Coastal Health Research Institute scientist Dr. Jason Andrade. 

The findings, published online in the New England Journal of Medicine in November 2020, were simultaneously presented at the American Heart Association’s Scientific Sessions 2020.

“Our research showed that cryoballoon ablation was better at preventing symptoms from recurring a little or at all, and reduced the amount of time some patients experienced atrial fibrillation,” says Andrade at the Centre for Cardiovascular Innovation. “This finding demonstrates that ablation may be a more effective first-line therapy for some patients.” 

Dr. Jason Andrade is the director of Cardiac Electrophysiology and the Atrial Fibrillation Clinic at Vancouver General Hospital and a clinical associate professor in the Department of Medicine, Division of Cardiology at the University of British Columbia.

AF occurs when electrical signals in the right upper chamber of the heart malfunction, causing the heart to flutter or beat irregularly. AF affects over 500,000 Canadians, and puts individuals with the condition at greater risk of developing stroke or heart failure.

One treatment for AF is catheter ablation, which involves threading a long, thin tube through blood vessels to the heart muscle. Cardiac electrophysiologists then administer extreme cold to freeze away tissues with the aim of restoring the heart’s natural rhythm.

Cryoballoon ablation involves using a small balloon filled with a gas coolant to freeze away faulty heart tissue.

Andrade’s study is the largest randomized clinical trial to clearly identify superior health outcomes from the use of cryoablation in comparison to AAD medication—the current first-line treatment for AF, which involves taking medication two to three times per day. 

Of the patients who received cryoballoon ablation, 57.1 per cent did not have a recurrence of some form of atrial tachyarrhythmia—an irregular heartbeat—by the one year mark compared with only 32.2 per cent of patients who received AAD. Eighty-nine per cent of cryoballoon ablation patients were free of symptomatic arrhythmia episodes, while this occurred for only 73.8 per cent of AAD patients.

All study participants received an implanted cardiac monitor that recorded their heart rhythm minute-to-minute and day-to-day over the course of the 12-month clinical trial.

The pan-Canadian study involved 18 health care centres and 303 participants who were treated for AF for the first time in their lives. Participants were on average around 58 years of age and approximately 73 per cent were male. Half of the cohort was randomly selected for cryoballoon ablation while the other half was treated with AAD.   

Addressing the root cause right away

Reduced quality of life is a major factor for people with AF. Andrade’s findings show that life satisfaction was slightly higher among cryoballoon ablation patients.

“At an extreme level, some patients may become incapacitated when they go into atrial fibrillation,” says Andrade. “Others who experience more mild-to-moderate symptoms may be unable or reluctant to pursue daily activities, such as traveling or engaging in physical activity. During an episode they may have shortness of breath and feel generally unwell.” 

“On top of the sometimes debilitating effects on patients, AF has a huge economic impact in terms of direct patient care and cost of essential health care resources, such as hospital visits, and indirect costs such as lost wages.” 

A 2012 study estimated that the Canadian health care system spends around $815 million on in-hospital AF patient care. And while cryoablation is a more invasive procedure with its own risks, it can offer greater returns than AAD by addressing the root cause of AF, rather than treating its symptoms, says Andrade. 

“All participants in the study fared better after receiving either procedure. However, patients who received cryoballoon ablation were more likely to be symptom-free and not require hospitalization for their atrial fibrillation.”

Andrade says that he and his research team plan to follow up with participants in three years to gather longitudinal data on the long-term impacts of both procedures. 
 

Researchers

Jason Andrade

Related Articles

Big data for better cardiac care

Early intervention with cryoablation for better heart outcomes

Keeping your head in the race: Cognitive impacts observed among ultra-marathon runners

Share:

  • Facebook
  • Linkedin
  • Twitter
  • Email

Related Research Centres/Programs

Centre for Cardiovascular Innovation

Get the latest research headlines in your inbox

Subscribe

Recent News and Stories

Type
Announcement

Investigator Awards 2023 Recipients

Mar 21, 2023 award
Type
Stories

Ask an expert: Is my menstrual pain normal, or could I have endometriosis?

Mar 16, 2023 women, endometriosis, preventative
Type
Stories

Honing in on precision treatments for endometriosis

Mar 14, 2023 genetics, treatment options
See more news

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy